

January 30, 2017

Intrathecal Therapy Business Disposition

On January 30, 2017, Mallinckrodt plc (Mallinckrodt or the company) announced that it had entered into an agreement to sell the rights to the company's Intrathecal Therapy business. The sale of the business does not qualify for treatment as a discontinued operation in accordance with accounting principles generally accepted in the United States (GAAP), and therefore historical sales and earnings results will not be recast to reflect the divestiture. Net sales of Intrathecal Therapy products are included within the Specialty Brands segment, and presented in the "Other" line for the net sales breakdown of this segment. The following Intrathecal net sales information is being provided for reference to demonstrate the significance of the Intrathecal business on a quarterly basis for the fiscal years ended September 30, 2016 and September 25, 2015:

MALLINCKRODT PLC
INTRATHECAL NET SALES
(unaudited, in millions)

	Fiscal Year Ended	
	September 30, 2016	September 25, 2015
First Quarter	\$ 10.4	\$ 9.8
Second Quarter	10.6	9.9
Third Quarter	11.3	10.2
Fourth Quarter	12.3	11.4
Full Fiscal Year	<u>\$ 44.6</u>	<u>\$ 41.3</u>